High-Dose Cisplatin Therapy for Cancer for the Ovary: Neurotoxicity

  1. CHARLES M. BAGLEY, JR., M.D.;
  2. ROBERT H. RUDOLPH, M.D.;
  3. SAUL E. RIVKIN, M.D.; and
  4. JOSEPH L. YON, JR., M.D.
  1. Puget Sound Oncology Consortium;
    Seattle, WA 98133

    Excerpt

    To the editor: We wish to call to your readers' attention an unexpectedly severe and disabling neurotoxicity due to very-high-dose cisplatin therapy for cancer of the ovary. The attainment of complete remission, proven by second-look surgery, is the first step toward achieving prolonged survival and cure of stage III cancer of the ovary. Recently, Ozols and associates (1) have reported that administration of very high doses of cisplatin (200 mg/m2 body surface area over 5 consecutive days) has achieved frequent tumor regression in patients with advanced cancer of the ovary previously refractory to conventional doses of cisplatin. To improve complete

    This 100-word excerpt has been provided in the absence of an abstract.

    | Table of Contents
    Most Read Most Read
    Most Commented Most Commented On
    Annals in the News Annals in the News
    Clinical Trials Clinical Trials
    Comparative Effectiveness Comparative Effectiveness
    Hospital Medicine Hospital Medicine
    • Advertisement
    • Advertisement